Three probiotic strains exert different effects on plasma bile acid profiles in healthy obese adults: randomised, double-blind placebo-controlled crossover study
| Autor: | Carley T. Rusch, Bobbi Langkamp-Henken, Tyler Culpepper, Cassie C. Rowe, Alyssa M. Burns, Thomas A. Tompkins, Stephanie-Anne Girard, A.P. Federico, Mary C. Christman, Jennifer C. Dennis-Wall, Carmelo Nieves |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Adult Male medicine.medical_specialty medicine.drug_class medicine.medical_treatment Blood lipids 030204 cardiovascular system & hematology Carbohydrate metabolism Microbiology law.invention Bile Acids and Salts Placebos 03 medical and health sciences Probiotic Feces Plasma 0302 clinical medicine Bifidobacterium animalis Double-Blind Method Gastrointestinal Agents law Internal medicine medicine Humans Obesity 030109 nutrition & dietetics Cross-Over Studies biology Bile acid business.industry Insulin Probiotics Metabolism Middle Aged biology.organism_classification Crossover study Endocrinology Treatment Outcome Female business Bacillus subtilis Lactobacillus plantarum |
| Zdroj: | Beneficial microbes. 10(5) |
| ISSN: | 1876-2891 |
| Popis: | Microbial metabolism in the gut may alter human bile acid metabolism in a way that beneficially affects lipid homeostasis and therefore cardiovascular disease risk. Deconjugation of bile acids by microbes is thought to be key to this mechanism but has yet to be characterised in blood and stool while observing lipid markers. The aim of this study was to determine the effect of 3 different probiotic strains on plasma and stool bile acids in the context of lipid and glucose metabolism. In this 18-week, randomised, double-blind crossover study, healthy adults (53±8 years) with a high waist circumference underwent a 1-week pre-baseline period and were then randomised to receive 1 capsule/day of Bacillus subtilis R0179 (2.5×109cfu/capsule; n=39), Lactobacillus plantarum HA-119 (5×109cfu/capsule; n=38), Bifidobacterium animalis subsp. lactis B94 (5×109cfu/capsule; n=37) or placebo for 6 weeks. Following a 3-week washout and second pre-baseline week, participants were crossed to the other intervention for 6 weeks followed by a 1-week post-intervention period. Blood and stool samples were collected at the beginning and end of each intervention to measure bile acids, serum lipid profiles, and glucose and insulin levels. Data from the placebo intervention were combined for all participants for analyses. In obese participants, the difference (final-baseline) in the sum of deconjugated plasma bile acids was greater with consumption of B. subtilis (691±378 nmol/l, P=0.01) and B. lactis (380±165 nmol/l, P=0.04) than with placebo (98±176 nmol/l, n=57). No significant differences were observed for any probiotics for stool bile acids, serum lipids, blood glucose or insulin. These data suggest that B. subtilis and B. lactis had no effect on glucose metabolism or serum cholesterol but increased deconjugated plasma bile acids in obese individuals. Additional studies should be conducted to confirm these findings and explore potential mechanisms. This trial was registered at clinicaltrials.gov as NCT01879098. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|